Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
112 participants
OBSERVATIONAL
2008-01-01
2024-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Management of Spontaneous Ruptured Hepatocellular Carcinoma
NCT03516890
A New Prognostic Scoring System for Spontaneous Ruptured Hepatocellular
NCT03504358
Recurrence of Hepatocellular Carcinoma
NCT01520779
Predictors and Outcome of Rupture HCC in AU Hospitals
NCT07291674
Identification of Image Phenotypes to Predict Recurrence After Resection of Hepatocellular Carcinoma
NCT05235490
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Cases had to be 18 years or older. They were identified by two different methodologies adapted to the 4 participating centers. In particular, a request for ICD10 C22.0 (CHC) codes associated with K66.1 (hemoperitoneum) was carried out by the medical information departments (DIM) of the Caen University Hospital and the Avicenne hospital. Secondly, the automated keyword selection tools "Cohort 360" and "i2b2" were used at the La Pitié Salpetrière and Paul Brousse hospital centers to identify the terms "CHC" and "ruptured" in the computerized patient files. Secondarily, duplicates and coding errors were excluded.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Other benign or malignant liver tumors
* ATCD of potentially triggering interventional procedure in the previous month.
* Hemorrhagic ascites without tumor
* Intratumoral hemorrhages without hemoperitoneum or capsular rupture
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Caen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
References
Explore related publications, articles, or registry entries linked to this study.
Commin A, Metivier C, Allaire M, Lubrano J, Claudinot A, Coilly A, Allard MA, Roux C, Scatton O, Nault JC, Sutter O, Ganne-Carrie N, Ngo TV, Goff VL, Ali ZB, Tedlaouti H, Papin J, Habireche M, Lebedel L, Perignon C, Dao T, Morello R, Ollivier-Hourmand I. Early Hemostatic Treatment Could Improve 30-Day Survival After Spontaneous Rupture of Hepatocellular Carcinoma. Liver Int. 2025 Oct;45(10):e70332. doi: 10.1111/liv.70332.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHCrompu
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.